Portal de Periódicos da CAPES

Biosynthesis of natural and halogenated plant monoterpene indole alkaloids in yeast

2023; Nature Portfolio; Volume: 19; Issue: 12 Linguagem: Inglês

10.1038/s41589-023-01430-2

1552-4469

Samuel A. Bradley, Beata Joanna Lehka, Frederik G. Hansson, Khem B. Adhikari, Daniela Rago, Paulina Rubaszka, Ahmad K. Haidar, Ling Chen, Lea G. Hansen, Olga Gudich, Konstantina Giannakou, Bettina Lengger, Ryan T. Gill, Yoko Nakamura, Thomas Dugé de Bernonville, Κωνσταντίνος Κουδούνας, David Romero-Suárez, Ling Ding, Yi‐Jun Qiao, Thomas M. Frimurer, Anja A. Petersen, Sébastien Besseau, Sandeep Kumar, Nicolas Gautron, C. Mélin, Jillian Marc, Remi Jeanneau, Sarah E. O’Connor, Vincent Courdavault, Jay D. Keasling, Jie Zhang, Michael K. Jensen,

Phytochemical Studies and Bioactivities

Abstract Monoterpenoid indole alkaloids (MIAs) represent a large class of plant natural products with marketed pharmaceutical activities against a wide range of indications, including cancer, malaria and hypertension. Halogenated MIAs have shown improved pharmaceutical properties; however, synthesis of new-to-nature halogenated MIAs remains a challenge. Here we demonstrate a platform for de novo biosynthesis of two MIAs, serpentine and alstonine, in baker’s yeast Saccharomyces cerevisiae and deploy it to systematically explore the biocatalytic potential of refactored MIA pathways for the production of halogenated MIAs. From this, we demonstrate conversion of individual haloindole derivatives to a total of 19 different new-to-nature haloserpentine and haloalstonine analogs. Furthermore, by process optimization and heterologous expression of a modified halogenase in the microbial MIA platform, we document de novo halogenation and biosynthesis of chloroalstonine. Together, this study highlights a microbial platform for enzymatic exploration and production of complex natural and new-to-nature MIAs with therapeutic potential.